Use Of Non-Inferiority Trials Could Increase Despite Unclear Guidance
Executive Summary
Regulators need to provide greater clarity on non-inferiority clinical trial designs, an Amgen exec said during FDA's 2006 Science Forum
You may also be interested in...
FDA To Consider Critical Path Trial Design Proposals On Case-By-Case Basis
FDA will generally take a case-by-case approach to considering and accepting development programs using clinical trial designs discussed in its Critical Path opportunities list
Biomarker Qualification Guidance To Require Fit For Use Validation
FDA's biomarker qualification guidance will establish a "fitness for use" standard for marker validation, Deputy Commissioner for Operations Janet Woodcock said
Progression-Free Survival Must Be Tied To Survival For Oncologic Approval
Progression-free survival will have to be validated as a surrogate for survival on a cancer-by-cancer basis for PFS to be considered as a valid endpoint for approval, comments by FDA and members of its Oncologic Drugs Advisory Committee suggest
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: